• Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732).
  
• Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Unspecified (PubMed=9598804).
  

PubMed=8027550; DOI=10.4049/jimmunol.153.3.1225
Marincola F.M., Shamamian P., Alexander R.B., Gnarra J.R., Turetskaya R.L., Nedospasov S.A., Simonis T.B., Taubenberger J.K., Yannelli J.R., Mixon A., Restifo N.P., Herlyn M., Rosenberg S.A.
Loss of HLA haplotype and B locus down-regulation in melanoma cell lines.
J. Immunol. 153:1225-1237(1994)

PubMed=8081556; DOI=10.1097/00002371-199407000-00002
Marincola F.M., Shamamian P., Simonis T.B., Abati A.D., Hackett J.A., O'Dea T., Fetsch P.A., Yannelli J.R., Restifo N.P., Mule J.J., Rosenberg S.A.
Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.
J. Immunother. Emphasis Tumor Immunol. 16:13-23(1994)

PubMed=8537970; DOI=10.1093/jnci/88.2.100
Restifo N.P., Marincola F.M., Kawakami Y., Taubenberger J.K., Yannelli J.R., Rosenberg S.A.
Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
J. Natl. Cancer Inst. 88:100-108(1996)

PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N
Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C., Fountain J.W.
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Genes Chromosomes Cancer 22:157-163(1998)

PubMed=9670966; DOI=10.4049/jimmunol.161.2.877
Bettinotti M.P., Kim C.J., Lee K.-H., Roden M., Cormier J.N., Panelli M.C., Parker K.K., Marincola F.M.
Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
J. Immunol. 161:877-889(1998)

PubMed=10048982; DOI=10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A
Cormier J.N., Panelli M.C., Hackett J.A., Bettinotti M.P., Mixon A., Wunderlich J.R., Parker L.L., Restifo N.P., Ferrone S., Marincola F.M.
Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model.
Int. J. Cancer 80:781-790(1999)

PubMed=15467732; DOI=10.1038/sj.onc.1208152
Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J., Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.
Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
Oncogene 23:8796-8804(2004)

PubMed=18172304; DOI=10.1158/0008-5472.CAN-07-1939
Sabatino M., Zhao Y.-D., Voiculescu S., Monaco A., Robbins P.F., Karai L., Nickoloff B.J., Maio M., Selleri S., Marincola F.M., Wang E.
Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis.
Cancer Res. 68:122-131(2008)

PubMed=21857157; DOI=10.4161/cc.10.17.17068
Caputo E., Maiorana L., Vasta V., Pezzino F.M., Sunkara S., Wynne K., Elia G., Marincola F.M., McCubrey J.A., Libra M., Travali S., Kane M.
Characterization of human melanoma cell lines and melanocytes by proteome analysis.
Cell Cycle 10:2924-2936(2011)